Travere Therapeutics (TVTX) EBT (2011 - 2026)

Travere Therapeutics has reported EBT for 16 years, with the latest figure at -$36.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 10.84% year-over-year to -$36.7 million; the trailing twelve-month figure through Mar 2026 stood at -$44.8 million (up 80.17% YoY), and the FY2025 full-year result was -$49.3 million, up 84.63% from the prior year.
• EBT for Q1 2026 stood at -$36.7 million, down from -$21.1 million in the prior quarter.
• The five-year high for EBT was $25.7 million in Q3 2025, with the low at -$135.8 million in Q1 2024.
• Historically, EBT has averaged -$65.5 million across 5 years, with a median of -$80.0 million in 2022.
• Annual changes were most pronounced in 2022 — EBT tumbled 135.75% — and 2025, when it jumped 146.89%.
• Travere Therapeutics' EBT stood at -$85.6 million in 2022, then retreated by 3.45% to -$88.5 million in 2023, then soared by 31.84% to -$60.3 million in 2024, then surged by 65.09% to -$21.1 million in 2025, then tumbled by 74.33% to -$36.7 million in 2026.
• The last three EBT figures came in at -$36.7 million (Q1 2026), -$21.1 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.